Sengkang Health

sengkanghealth.com.sg

Sengkang Health forms a vital part of Singapore’s master plan in providing innovative, quality and accessible healthcare to our vibrant island nation of over five million people. Nestled in the northeast heartland, it will offer cutting-edge general hospital competencies with community-based care. As a member of SingHealth, Singapore’s largest academic healthcare cluster, Sengkang General and Community Hospitals will augment SingHealth’s infrastructure in delivering a full spectrum of care to meet our population’s growing healthcare needs. With a strong community focus, Sengkang Health envisions building an ecosystem of healthy living for the benefit of residents in northeast Singapore.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

TEVOGEN BIO PARTNERED WITH NEAL FLOMENBERG TO EVALUATE TEVOGEN' S PROPRIETARY ANTIGEN-SPECIFIC T-CELL TECHNOLOGY AS A TREATMENT FOR COVID-19

Tevogen Bio | August 11, 2020

news image

Tevogen Bio believes that its investigational highly purified antigen-specific T cell therapy holds promise in the treatment of viral infections including COVID-19 and Influenza A. This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation. Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expert Neal Flomenb...

Read More

Cell and Gene Therapy, Industrial Impact

EDITAS MEDICINE ANNOUNCES PUBLICATION IN NATURE BIOTECHNOLOGY OF COMPREHENSIVE SLEEK GENE EDITING TECHNOLOGY DATA

Globenewswire | May 02, 2023

news image

Editas Medicine, Inc. a clinical stage genome editing company, announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK gene editing technology. Despite major progress in achieving gene disruption with CRISPR-Cas gene editing technologies, efficient knock-in of transgenes continues to be a significant challenge for the gene editing field. To solve this challenge, SLEEK was developed to enable high knock-in efficiency ...

Read More

Industrial Impact

GILEAD SCIENCES TO ACQUIRE MIROBIO

Gilead Sciences, Inc. | August 05, 2022

news image

Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of imm...

Read More

Medical

OCHRE BIO LAUNCHES ‘LIVER ICU’ IN THE UNITED STATES TO EVALUATE EFFECTS OF RNA THERAPIES ON HUMAN LIVER PERFORMANCE

Ochre Bio | May 12, 2022

news image

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced today the launch of their ‘Liver ICU’. Housed in BioLabs@NYULangone, a biopharma incubator in New York City, this research site will evaluate the efficacy of new RNA therapeutics on whole human livers maintained on machines. The use of discarded donor livers for research is expected to enhance timelines and accuracy of liver medicine research by testing interventions directly in human livers m...

Read More
news image

TEVOGEN BIO PARTNERED WITH NEAL FLOMENBERG TO EVALUATE TEVOGEN' S PROPRIETARY ANTIGEN-SPECIFIC T-CELL TECHNOLOGY AS A TREATMENT FOR COVID-19

Tevogen Bio | August 11, 2020

Tevogen Bio believes that its investigational highly purified antigen-specific T cell therapy holds promise in the treatment of viral infections including COVID-19 and Influenza A. This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation. Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expert Neal Flomenb...

Read More
news image

Cell and Gene Therapy, Industrial Impact

EDITAS MEDICINE ANNOUNCES PUBLICATION IN NATURE BIOTECHNOLOGY OF COMPREHENSIVE SLEEK GENE EDITING TECHNOLOGY DATA

Globenewswire | May 02, 2023

Editas Medicine, Inc. a clinical stage genome editing company, announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK gene editing technology. Despite major progress in achieving gene disruption with CRISPR-Cas gene editing technologies, efficient knock-in of transgenes continues to be a significant challenge for the gene editing field. To solve this challenge, SLEEK was developed to enable high knock-in efficiency ...

Read More
news image

Industrial Impact

GILEAD SCIENCES TO ACQUIRE MIROBIO

Gilead Sciences, Inc. | August 05, 2022

Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of imm...

Read More
news image

Medical

OCHRE BIO LAUNCHES ‘LIVER ICU’ IN THE UNITED STATES TO EVALUATE EFFECTS OF RNA THERAPIES ON HUMAN LIVER PERFORMANCE

Ochre Bio | May 12, 2022

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced today the launch of their ‘Liver ICU’. Housed in BioLabs@NYULangone, a biopharma incubator in New York City, this research site will evaluate the efficacy of new RNA therapeutics on whole human livers maintained on machines. The use of discarded donor livers for research is expected to enhance timelines and accuracy of liver medicine research by testing interventions directly in human livers m...

Read More

Resources

resource image

Cell and Gene Therapy, Industrial Impact

Single-cell RNA Sequencing and Analysis

Video

resource image

Cell and Gene Therapy

BCIT Biotechnology

Video

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

resource image

Cell and Gene Therapy

bFGF Supports Human ES Cell Self-Renewal

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Single-cell RNA Sequencing and Analysis

Video

resource image

Cell and Gene Therapy

BCIT Biotechnology

Video

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

resource image

Cell and Gene Therapy

bFGF Supports Human ES Cell Self-Renewal

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us